Article
Highlights from Tuesday, day 3 of the ACR Annual meeting in Chicago, included the PEXIVAS Study, ACR Reproductive Health Draft Guidelines, and a Proof of concept study
All News
Article
2019 was a year marked by major advances, hallmark research, and big news items affecting rheumatology. Herein you will find our top 10 list, formulated by what I think rheumatologists should know and what will likely change their standards and practice in 2020 and beyond.
Article
Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released the 2019 ACR/AF Guideline for the Management of Osteoarthritis of the Hand, Hip and Knee.
Article
Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA).
Article
Dr. Jack Cush reviews highlights from 2019 on RheumNow.com. Topics covered in this annual review include: superheroes lost; venous thromboembolic events and JAKs; free medical tuition; women in rheumatology; 52 new drug approvals in 2019 and 330 drugs with a 2020 price hike; scleroderma disappointments; novel new treatments and newer tests; the boom of Shingrix; RheumNow.Live - and more.
Dr. John Cush
Tweet
Dr. Heidi Jacobi #UTSW says Raynauds, puffy digits and a +ANA should raise suspicion of systemic sclerosis. Also Carol tunnel syndrome may be a presenting feature
Dr. John Cush
Tweet
Dr. Heidi Jacobi #UTSW lecturing on scleromyxedema often with "pebble like" lesions that during it from scleroderma https://t.co/5odVXrglyT
Dr. John Cush
Tweet
#UTSW Rheumatology grand rounds with Dr Heidi Jacobi . Serologic and lab findings in patients with MOPHEA https://t.co/d619QnYrZ9
Dr. John Cush
Tweet
Toscana is an arbovirus transmitted by sand flies in the Mediterranean. May fever, neuroinvasive infections & is an important cause of meningitis and encephalitis. May also cause Guillain-Barré, myositis, fasciitis, polymyeloradiculopathy, deafness, https://t.co/9X4OwAqRF9
Dr. John Cush
Tweet
Misuse and abuse of Gabapentin in US? Between 2003-2016 there were 260 million gabapentinoid visits. Annual use nearly quadrupled from 2003 to 2016 (mostly PCPs 46%). Nearly half w/ concurrent opioids (32.9%) or benzodiazepines (15.3%). https://t.co/Wnja1mkDQo
Dr. John Cush
Tweet
Systematic literature of biologic Rx of dactylitis & enthesitis in Psoriatic arthritis. 18 trials, 6981 patients showed that TNF inhib & ustekinumab, secukinumab, ixekizumab were 2-3 fold significantly better than PBO at resolution of dactylitis by Wk 24. https://t.co/HlQcw5cXsN
Dr. John Cush
Tweet
301 fibromyalgia #FM pts randomized to receive active‐TENS or placebo‐TENS or no‐TENS to use at home 2h/day for 4 wks. Active TENS had greater reduction in pain & fatigue vs placeboAND better global improvement (70% vs. 31%, p<0.0001) https://t.co/AH84DxlTo3
Dr. John Cush
Tweet
CORRONA registry 880 RA pts developed a solid cancer. 42% taking bDMARD/tsDMARD; 5% switched biologics w/in 36 mos & 10% started a new biologic- w/ most changing to a TNFi (53%). ACR guidelines say to Rx regardless of solid tumor https://t.co/pPgnYNdT7Q
Dr. John Cush
Tweet
high-dose trivalent inactivated influenza vaccine (HD-TIV) was studied in 696 RA patients compared to standard-dose quadrivalent flu vaccine - Seroconversion was 3 fold higher w/ HD-TIV, no differences in side effects and no increase in RA flares https://t.co/1JBs95vGSA
Dr. John Cush
Tweet
Claims data from RA patients (n = 12,182), shows that screening for hyperlipidemia was suboptimal (compared to Diabetes pts), Those seeing a PCP and Rheum were 36% more likely to be screened. https://t.co/j661loTDGk
Dr. John Cush
Tweet
From the 9/11 World Trade Center registry, 118 persons found w/ a CTD (RA=71, Sjӧgrens 22, SLE 20, myositis 9,MCTD 7, PSS 4. Responders w/ intense dust cloud exposure had 2 fold CTD risk & Community members w/ PTSD had 3‐fold risk. https://t.co/07GhloezNA
Dr. John Cush
Tweet
2019 YEAR IN REVIEW Podcast is up! Superheros, women, New Drugs, Novel Approaches, Failed drugs, MTX, Who's killing medicine & low dose pred Watch here>> https://t.co/sYb3KvivJK or Podcast Listen on iTunes https://t.co/FlPe6BQ3BW or Soundcloud >> https://t.co/FlPe6BQ3BW
Dr. John Cush
Tweet
2019 YEAR IN REVIEW Podcast is up! Superheros, women, New Drugs, Novel Approaches, Failed drugs, MTX, Who's killing medicine & low dose pred Watch here>> https://t.co/sYb3KvivJK or Podcast Listen on iTunes https://t.co/FlPe6BQ3BW or Soundcloud >> https://t.co/FlPe6BQ3BW
Dr. John Cush
Tweet
Check out my 2019 Rheumatology Year in Review - now on RheumNow https://t.co/sYb3KvivJK
Dr. John Cush
Tweet
Rates of "indeterminate" results on quantiferon-IT assays were found to be significantly higher in systemic vasculitis (21%) than nonvasculitis pts and controls (7-7.5%). Indeterminate predictors were Syst vasculitis (OR 9.64), high NLR (OR 1.70). https://t.co/roZINmKgZ1
